The study will test the drug ifetroban in patients who have completed cancer treatment for one of five cancer types and have no evidence of disease, but who are at very high risk for cancer recurrence.
Now in a study published in the journal PLOS ONE, Vsevolod Gurevich, PhD, and colleagues show that a glycine residue at the beginning of the finger loop is critical for the arrestin-GPCR interaction.
